Tags

Type your tag names separated by a space and hit enter

Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers.
BMC Neurosci. 2016 Feb 01; 17:6.BN

Abstract

BACKGROUND

Bilateral subthalamic nucleus deep brain stimulation (STN-DBS) of parkinson's disease (PD) patients has demonstrated to improve motor performance and to reduce dopa-induced dyskinesia. An association between the occurrence of dyskinesias and LRRK2 (leucine-rich repeat kinase 2) G2019S gene mutations has recently been suggested. The aim of this study is to discover the impact of the G2019S mutation (with high incidence in the authors' native Algeria) on the symptom response of PD in patients who underwent STN-DBS.

METHODS

We carried out a comparative statistical study for the clinical evaluation and neuropsychological assessment of 27 Algerian PD STN-DBS patients, both G2019S mutation carriers (MC) and non-carriers (NC). A multiple correspondence analysis (MCA) was then conducted to compare the results with those from groups of individuals with similar modalities.

RESULTS

The MCA revealed that MC and NC PD patients showed two different patterns of clinical evaluations. The group of idiopathic patients showed some differences compared to the clinical evaluations, depending on gender. No association was found between the G2019S mutation and the Mini Mental State Examination scores (MMSE), and MC patients appeared more susceptible to dyskinesia than NC patients. In NC patients, we found two cases with Parkin mutations who had a different "honeymoon" period and different initial symptoms. The results showed considerable improvement of motor unified parkinson's disease rating scale III (UPDRS-III) in a situation of stimulation without medication in the MC patients with a percentage of improvement (51.1 %) over the required 30 % compared to the NC patients (25.5 %). The same result was observed for the Schwab and England's activities of daily living scale (S and E scale), which thus demonstrated a greater effectiveness of DBS for MC patients than for NC patients. However, the Hoehn and Yahr scale (H and Y Scale) showed the same significance in a situation of stimulation for MC and NC patients. In this later group, the best scores of UPDRS-III were observed for patients with the Parkin mutation before they underwent surgery.

CONCLUSIONS

This study shows that surgical treatment probably has a more significant impact on LRRK2 G2019S MC than on idiopathic patients.

Authors+Show Affiliations

Laboratory of Behavioral and Cognitive Neuroscience, FSB, University of Science and Technology Houari Boumediene, El Alia, Bab Ezzouar, BP 32, 16111, Algiers, Algeria. sayad_massiva@yahoo.fr. Department of BPO, Faculty of SNV, Blida 1 University, BP 270, 09000, Blida, Algeria. sayad_massiva@yahoo.fr.Laboratory of Behavioral and Cognitive Neuroscience, FSB, University of Science and Technology Houari Boumediene, El Alia, Bab Ezzouar, BP 32, 16111, Algiers, Algeria. zouambia26@gmail.com.Department of Neurology, CHU Ben Aknoun, 16000, Algiers, Algeria. chaouch_malika@hotmail.com.Department of Neurology, CHU Ben Aknoun, 16000, Algiers, Algeria. ferratfarida@yahoo.fr.Department of Neurosurgery, Mohamed-Seghir Nekkache Military Hospital, Djasr Kasentina, Algiers, Algeria. mus.neuro@gmail.com.Department of Neurology, Mohamed-Seghir Nekkache Military Hospital, Djasr Kasentina, Algiers, Algeria. m-bendini@hotmail.fr.UMR S 1127 PaInserm U 1127, Sorbonne University, UPMC Univ Paris 06, Paris, France. suzanne.lesage@upmc.fr. CNRS UMR 7225, Paris, France. suzanne.lesage@upmc.fr. The Brain and Spinal Cord Institute, 75013, Paris, France. suzanne.lesage@upmc.fr.UMR S 1127 PaInserm U 1127, Sorbonne University, UPMC Univ Paris 06, Paris, France. alexis.brice@upmc.fr. CNRS UMR 7225, Paris, France. alexis.brice@upmc.fr. The Brain and Spinal Cord Institute, 75013, Paris, France. alexis.brice@upmc.fr.Department of Chemistry, Blida 1 University, BP 270, 09000, Blida, Algeria. m.brahim.errahmani@univ-blida.dz.Laboratory of Behavioral and Cognitive Neuroscience, FSB, University of Science and Technology Houari Boumediene, El Alia, Bab Ezzouar, BP 32, 16111, Algiers, Algeria. asselah.boualem@gmail.com.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

26831335

Citation

Sayad, Massiva, et al. "Greater Improvement in LRRK2 G2019S Patients Undergoing Subthalamic Nucleus Deep Brain Stimulation Compared to Non-mutation Carriers." BMC Neuroscience, vol. 17, 2016, p. 6.
Sayad M, Zouambia M, Chaouch M, et al. Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers. BMC Neurosci. 2016;17:6.
Sayad, M., Zouambia, M., Chaouch, M., Ferrat, F., Nebbal, M., Bendini, M., Lesage, S., Brice, A., Brahim Errahmani, M., & Asselah, B. (2016). Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers. BMC Neuroscience, 17, 6. https://doi.org/10.1186/s12868-016-0240-4
Sayad M, et al. Greater Improvement in LRRK2 G2019S Patients Undergoing Subthalamic Nucleus Deep Brain Stimulation Compared to Non-mutation Carriers. BMC Neurosci. 2016 Feb 1;17:6. PubMed PMID: 26831335.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Greater improvement in LRRK2 G2019S patients undergoing Subthalamic Nucleus Deep Brain Stimulation compared to non-mutation carriers. AU - Sayad,Massiva, AU - Zouambia,Mohamed, AU - Chaouch,Malika, AU - Ferrat,Farida, AU - Nebbal,Mustapha, AU - Bendini,Mohamed, AU - Lesage,Suzanne, AU - Brice,Alexis, AU - Brahim Errahmani,Mohamed, AU - Asselah,Boualem, Y1 - 2016/02/01/ PY - 2015/04/22/received PY - 2016/01/17/accepted PY - 2016/2/3/entrez PY - 2016/2/3/pubmed PY - 2016/10/13/medline SP - 6 EP - 6 JF - BMC neuroscience JO - BMC Neurosci VL - 17 N2 - BACKGROUND: Bilateral subthalamic nucleus deep brain stimulation (STN-DBS) of parkinson's disease (PD) patients has demonstrated to improve motor performance and to reduce dopa-induced dyskinesia. An association between the occurrence of dyskinesias and LRRK2 (leucine-rich repeat kinase 2) G2019S gene mutations has recently been suggested. The aim of this study is to discover the impact of the G2019S mutation (with high incidence in the authors' native Algeria) on the symptom response of PD in patients who underwent STN-DBS. METHODS: We carried out a comparative statistical study for the clinical evaluation and neuropsychological assessment of 27 Algerian PD STN-DBS patients, both G2019S mutation carriers (MC) and non-carriers (NC). A multiple correspondence analysis (MCA) was then conducted to compare the results with those from groups of individuals with similar modalities. RESULTS: The MCA revealed that MC and NC PD patients showed two different patterns of clinical evaluations. The group of idiopathic patients showed some differences compared to the clinical evaluations, depending on gender. No association was found between the G2019S mutation and the Mini Mental State Examination scores (MMSE), and MC patients appeared more susceptible to dyskinesia than NC patients. In NC patients, we found two cases with Parkin mutations who had a different "honeymoon" period and different initial symptoms. The results showed considerable improvement of motor unified parkinson's disease rating scale III (UPDRS-III) in a situation of stimulation without medication in the MC patients with a percentage of improvement (51.1 %) over the required 30 % compared to the NC patients (25.5 %). The same result was observed for the Schwab and England's activities of daily living scale (S and E scale), which thus demonstrated a greater effectiveness of DBS for MC patients than for NC patients. However, the Hoehn and Yahr scale (H and Y Scale) showed the same significance in a situation of stimulation for MC and NC patients. In this later group, the best scores of UPDRS-III were observed for patients with the Parkin mutation before they underwent surgery. CONCLUSIONS: This study shows that surgical treatment probably has a more significant impact on LRRK2 G2019S MC than on idiopathic patients. SN - 1471-2202 UR - https://www.unboundmedicine.com/medline/citation/26831335/Greater_improvement_in_LRRK2_G2019S_patients_undergoing_Subthalamic_Nucleus_Deep_Brain_Stimulation_compared_to_non_mutation_carriers_ L2 - https://bmcneurosci.biomedcentral.com/articles/10.1186/s12868-016-0240-4 DB - PRIME DP - Unbound Medicine ER -